Literature DB >> 10882648

Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation.

J L Fahey1, N Aziz, J Spritzler, S Plaeger, P Nishanian, J L Lathey, J Seigel, A L Landay, R Kilarui, J L Schmitz, C White, D W Wara, R Akridge, J Cutili, S D Douglas, J Reuben, W T Shearer, M Nokta, R Polland, R Schooley, D Asthana, Y Mizrachi, M Waxdal.   

Abstract

An external evaluation program for measuring the performance of laboratories testing for cytokines and immune activation markers in biological fluids was developed. Cytokines, chemokines, soluble cytokine receptors, and other soluble markers of immune activation (CSM) were measured in plasma from a healthy human immunodeficiency virus (HIV)-seronegative reference population and from HIV-seropositive individuals as well as in supernatant fluids from in vitro-stimulated human immune cells. The 14 components measured were tumor necrosis factor (TNF) alpha, gamma interferon, interleukin-1 (IL-1), IL-2, IL-4, IL-6, IL-10, Rantes, MIP-Ia, MIP-Ibeta, soluble TNF receptor II, soluble IL-2 receptor alpha, beta(2)-microglobulin, and neopterin. Twelve laboratories associated with the Adult and Pediatric AIDS Clinical Trial Groups participated in the study. The performance features that were evaluated included intralaboratory variability, interlaboratory variability, comparison of reagent sources, and ability to detect CSM in the plasma of normal subjects as well as the changes occurring in disease. The principal findings were as follows: (i) on initial testing, i.e., before participating in the program, laboratories frequently differed markedly in their analytic results; (ii) the quality of testing of a CSM in individual participating laboratories could be assessed; (iii) most commercial kits allowed distinction between normal and abnormal plasma CSM levels and between supernatants of stimulated and unstimulated cells; (iv) different sources of reagents and reference standards frequently provided different absolute values; (v) inexperienced laboratories can benefit from participating in the program; (vi) laboratory performance improved during active participation in the program; and (vii) comparability between analyses conducted at different sites can be ensured by an external proficiency testing program.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882648      PMCID: PMC95910          DOI: 10.1128/CDLI.7.4.540-548.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  18 in total

Review 1.  WHO cytokine standardization: facilitating the development of cytokines in research, diagnosis and as therapeutic agents.

Authors:  A R Mire-Sluis; R G Das; A Padilla
Journal:  J Immunol Methods       Date:  1998-07-01       Impact factor: 2.303

Review 2.  Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection.

Authors:  J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

3.  Standardization and calibration of cytokine immunoassays: meeting report and recommendations.

Authors:  M Wadhwa; R Thorpe
Journal:  Cytokine       Date:  1997-11       Impact factor: 3.861

4.  CD69, CD25, and HLA-DR activation antigen expression on CD3+ lymphocytes and relationship to serum TNF-alpha, IFN-gamma, and sIL-2R levels in aging.

Authors:  I M Rea; S E McNerlan; H D Alexander
Journal:  Exp Gerontol       Date:  1999-01       Impact factor: 4.032

5.  Implications for the assay and biological activity of interleukin-8: results of a WHO international collaborative study.

Authors:  A R Mire-Sluis; R Gaines Das; R Thorpe
Journal:  J Immunol Methods       Date:  1997-01-15       Impact factor: 2.303

6.  Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures.

Authors:  N Aziz; P Nishanian; J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

7.  Variables that affect assays for plasma cytokines and soluble activation markers.

Authors:  N Aziz; P Nishanian; R Mitsuyasu; R Detels; J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

Review 8.  Psychoneuroimmunology and aging.

Authors:  L Guidi; A Tricerri; D Frasca; M Vangeli; A R Errani; C Bartoloni
Journal:  Gerontology       Date:  1998       Impact factor: 5.140

9.  Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases.

Authors:  A Propst; T Propst; M Herold; W Vogel; G Judmaier
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-11       Impact factor: 2.566

10.  Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements.

Authors:  J L Fahey; J M Taylor; B Manna; P Nishanian; N Aziz; J V Giorgi; R Detels
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

View more
  6 in total

Review 1.  Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Authors:  Lisa H Butterfield; A Karolina Palucka; Cedrik M Britten; Madhav V Dhodapkar; Leif Håkansson; Sylvia Janetzki; Yutaka Kawakami; Thomas-Oliver Kleen; Peter P Lee; Cristina Maccalli; Holden T Maecker; Vernon C Maino; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Graham Pawelec; Douglas M Potter; Licia Rivoltini; Lupe G Salazar; Dolores J Schendel; Craig L Slingluff; Wenru Song; David F Stroncek; Hideaki Tahara; Magdalena Thurin; Giorgio Trinchieri; Sjoerd H van Der Burg; Theresa L Whiteside; Jon M Wigginton; Francesco Marincola; Samir Khleif; Bernard A Fox; Mary L Disis
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

2.  Multisite comparison of high-sensitivity multiplex cytokine assays.

Authors:  Elizabeth Crabb Breen; Sandra M Reynolds; Christopher Cox; Lisa P Jacobson; Larry Magpantay; Candice B Mulder; Oliver Dibben; Joseph B Margolick; Jay H Bream; Elise Sambrano; Otoniel Martínez-Maza; Elizabeth Sinclair; Persephone Borrow; Alan L Landay; Charles R Rinaldo; Philip J Norris
Journal:  Clin Vaccine Immunol       Date:  2011-06-22

Review 3.  Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era?

Authors:  Amy C Justice; Kristine M Erlandson; Peter W Hunt; Alan Landay; Paolo Miotti; Russell P Tracy
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

4.  Measurement of Circulating Cytokines and Immune-Activation Markers by Multiplex Technology in the Clinical Setting: What Are We Really Measuring?

Authors:  Najib Aziz
Journal:  For Immunopathol Dis Therap       Date:  2015

5.  Development of a proficiency testing program for the HIV-1 BED incidence assay in China.

Authors:  Hao Yan; Haiying Yu; Wenge Xing; Yao Xiao; Hui Zhang; Lijian Pei; Na Zhang; Yan Jiang
Journal:  Sci Rep       Date:  2014-03-28       Impact factor: 4.379

6.  Serum neopterin levels in patients with replicative and nonreplicative HBV carriers.

Authors:  Ilknur Kaleli; Melek Demir; Nural Cevahir; Mustafa Yilmaz; Suleyman Demir
Journal:  BMC Infect Dis       Date:  2006-10-31       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.